KURA Kura Oncology, Inc.
Healthcare$10.41-7.47%ClosedMarket Cap: $924.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
9.24
P/S
13.94
EV/EBITDA
-3.30
DCF Value
$19.88
FCF Yield
-8.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.7%
Operating Margin
-443.5%
Net Margin
-411.2%
ROE
-142.0%
ROA
-45.1%
ROIC
-57.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $18.3M | 96.6% | $-78.8M | $-73.3M | $— | — |
| Q4 null | $17.3M | 100.0% | $-86.3M | $-81.0M | $— | — |
| FY null | $67.5M | 99.9% | $-303.6M | $-278.7M | $— | — |
| Q3 null | $20.8M | 84.5% | $-80.0M | $-74.1M | $— | — |
| Q2 null | $15.3M | 100.0% | $-72.7M | $-66.1M | $— | — |
| Q1 null | $14.1M | 100.0% | $-64.7M | $-57.4M | $— | — |
| Q4 null | $53.9M | 100.0% | $-22.5M | $-19.2M | $— | — |
| FY null | $53.9M | 100.0% | $-193.2M | $-174.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-59.9M | $-54.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-56.4M | $-50.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-54.5M | $-49.5M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-46.8M | $-42.8M | $-0.55 | — |